Recent advances in intravenous delivery of poorly water-soluble compounds

Expert Opinion on Drug Delivery

Volumn 6, Issue 12, 2009, Pages 1261-1282

  Shi, Yi ^a   Porter, William ^a   Merdan, Thomas ^b   Li, Luk Chiu ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Cochleate; Complexing agent; Cyclodextrin; Dendrimer; I.v. formulation; Liposome; Liquid crystalline nanoparticle; Nanoparticle; Polymeric micellar system; Prodrug

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; AMIODARONE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; APREPITANT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CALCITRIOL; CEREBRYX; CREMOPHOR; CYCLODEXTRIN DERIVATIVE; DENDRIMER; DISSOCUBES; DODECYL SULFATE SODIUM; DRF 4367; FENOFIBRATE; FOSPROPOFOL; HDDS; IRINOTECAN; ISOXAZOLE DERIVATIVE; ITRACONAZOLE; LINTEC; LUSEDRA; MEGLUMINE; MITOEXTRA; MITOMYCIN; MITOMYCIN C; NANOCRYSTAL; NANOEDGE; NANOMATERIAL; NANOMORPH; NANOPURE; NAPROXEN; NARINGENIN; NSC 639829; OTAXIO; PACLITAXEL; PLURONICS; POLYSORBATE; POLYSORBATE 20; POLYSORBATE 80; POVIDONE; PROPOFOL; PROSTAGLANDIN E1; PROSTAVASIN; RAPAMYCIN; RIGIDUR; SULFAFURAZOLE; TEBOROXIME TC 99M; TRIETHANOLAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN; VINPOCETINE; VORICONAZOLE; XYTOTAX; ZIPRASIDONE;

AQUEOUS SOLUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFUSIONS, INTRAVENOUS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 71249130735     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903307423     Document Type: Review

References (147)

1. Timpe C. Strategies for formulating development of poorly water-soluble drug candidates - a recent perspective. Am Pharm Rev 2007;0(3):104-109
2. Liu R. Water insoluble drug formulation, 2nd edition, Boca Raton, FL: CRC Press, Taylor & Francis Group; 2008 . A key reference for various water-insoluble drug formulation approaches.
3. Duma RJ, Akers MJ, Turco SJ. Parenteral drug administration: routes, precautions, problems, complications, and drug delivery systems, chapter
4. In: Avis KE, Lieberman HA, Lachman L, editors, Pharmaceutical dosage forms: parenteral medications, 2nd edition New York NY: Marcel Dekker, Inc.; 1992. p. 17-58 . A key reference describing basic considerations in parenteral drug administration.
5. Duma RJ, Akers MJ, Turco SJ. Particulate matter in injections. USP 32-NF 27 S1 <788>, Rockville, MD: United States Pharmacopeia; 2009
6. DeLuca PP, Boylan JC. Formulation of small volume parenterals, chapter
7. In: Avis KE, Lieberman HA, Lachman L, editors, Pharmaceutical dosage forms: parenteral medications. 2nd edition. New York NY: Marcel Dekker, Inc.; 1992. p. 173-248 . A key reference describing the development of small volume parenteral formulations.
8. Yalkowsky SH. Solubility and solubilization in aqueous media. Washington, D.C.: American Chemical Society; 1999 . A key reference for estimation of solubility properties.
9. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-230
10. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335-351 . A key reference for formulation approaches using cyclodextrin complexation.
11. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001;225:15-30
12. Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005;302:18-28
13. Al-Soufi W, Cabrer PR, Jover A, et al. Determination of second-order association constants by global analysis of 1H and 13C NMR chemical shifts. Application to the complexation of sodium fusidate and potassium helvolate by beta- and gamma-cyclodextrin. Steroids 2003;68:43-53
14. Liu Y, Chen GS, Chen Y, et al. Inclusion complexes of paclitaxel and oligo (ethylenediamino) bridged bis (beta-cyclodextrin)s: solubilization and antitumor activity. Bioorg Med Chem 2004;12:5767-5775
15. Wen X, Liu Z, Zhu T, et al. Evidence for the 2:1 molecular recognition and inclusion behaviour between beta- and gamma-cyclodextrins and cinchonine. Bioorg Chem 2004;32:223-233
16. Vargas-Berenguel A, Ortega-Caballero F, Santoyo-Gonzalez F, et al. Dendritic galactosides based on a beta-cyclodextrin core for the construction of site-specific molecular delivery systems: synthesis and molecular recognition studies. Chemistry 2002;8:812-827
17. Kolhe P, Misra E, Kannan RM, et al. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143-160
18. Boas U, Sontjens SH, Jensen KJ, et al. New dendrimer peptide host guest complexes: towards dendrimers as peptide carriers. Chembiochem 2002;3:433-439
19. Kannan S, Kolhe P, Raykova V, et al. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomater Sci Polym Ed 2004;15:311-330
20. Fuchs S, Otto H, Jehle S, et al. Fluorescent dendrimers with a peptide cathepsin B cleavage site for drug delivery applications. Chem Commun (Camb) 2005;1830-1832
21. Patri AK, Kukowska-Latallo JF, Baker JR Jr Targeted drug delivery with dendrimers. comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005;57:2203-2214
22. Dhanikula RS, Hildgen P. Synthesis and evaluation of novel dendrimers with a hydrophilic interior as nanocarriers for drug delivery. Bioconjug Chem 2006;17:29-41
23. Bermejo JF, Ortega P, Chonco L, et al. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry 2007;13:483-495
24. SoluBestWater soluble nanoparticles inclusion complexes. WO2005030257; 2005
25. Halford B. Molecules get suited up. Chem Eng News 2006;84(42):11
26. Hussain R, Siligardi G. Fat-free albumin as a novel drug delivery system. Int J Peptide Res Ther 2006;2(3):311-315
27. Wunder A, Müller-Ladner U, Stelzer EH, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003;170:4793-4801
28. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-1598
29. Ten Tije AJ, Verweij J, Loos WJ, Sparreboon A. Pharmacological effects of formulation vehicles: Implications for cancer chemotheraphy. Clin Pharmacokinet 2003;42(7):665-685
30. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006;112:630-648
31. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Exp Opin Drug Deliv 2006;3(1):139-162
32. Torchilin VP. Block copolymer micelles as a solution for drug delivery problems. Expert Opin Ther Patents 2005;15(1):63-75
33. Lavasanifar A, Samuel J, Kwon GS. Poly (ethylene oxide)-block-poly(L- amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002;54:169-190
34. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003;92:1343-1355
35. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82(2-3):189-212
36. Le GD, Gori S, Luo L, et al. Poly (N-vinylpyrrolidone)-block-poly(D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 2004;99:83-101
37. Benahmed A, Ranger M, Leroux JC. Novel polymeric micelles based on the amphiphilic diblock copolymer poly (N-vinyl-2-pyrrolidone)-block-poly(D, L-lactide). Pharm Res 2001;18:323-328
38. Gaucher G, Dufresne MH, Sant VP, et al. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005;109:169-188
39. Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 2002;15:115-133
40. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002;19:1-72
41. Kozlov MY, Milik-Nubarov NS, Batrakova EV, Kabanov AV. Relationship between Pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes. Macromolecules 2000;33:3305-3313
42. Meadows JSynergistic mixed Poloxamers for the solubilization of drugs. US20040258718A1; 2004
43. Danson S, Ferry D, Alakhov V, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004;90:2085-2091
44. Allen C, Han J, Yu Y, et al. Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J Control Release 2000;63:275-286
45. Leung SY, Jackson J, Miyake H, et al. Polymeric micellar paclitaxel phosphorylates Bcl 2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate 2000;44:156-163
46. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-3716
47. Park SR, Oh DY, Kim DW, et al. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004;12:1059-1064
48. Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004;91:1775-1781
49. Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, a paclitaxel- incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005;92:1240-1246
50. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001;74:295-302
51. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res 2002;9:1424-1429
52. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-284
53. Liu SQ, Wiradharma N, Gao SJ, et al. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 2007;28:1423-1433
54. Soga O, Van Nostrum CF, Fens M, et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 2005;103:341-353
55. Lee ES, Shin HJ, Na K, Bae YH. Poly (L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release 2003;90:363-374
56. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 2007;118:216-224
57. Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm 2006;62:235-240
58. Lukyanov AN, Gao Z, Torchilin VP. Micelles from polyethylene glycol/ phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 2003;91:97-102
59. Park EK, Kim SY, Lee SB, Lee YM. Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 2005;109:158-168
60. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004;96:273-283
61. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-796
62. Mouton JW, Van Peer A, De Beule K, et al. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006;50:4096-4102
63. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318
64. Kipp, JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004;284:109-122
65. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-120
66. Moschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004;58:615-619
67. Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008;60:939-954
68. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008;36:43-48
69. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3-16
70. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19
71. Müller RH, Benita S, Böhm BHL. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart, Germany: Medpharm Scientific Publishers; 1998
72. DissoCubes. SkyePharma PLC, London, UK, 2008. Available from: www. skyepharma.com/technology/oral technology/particle engineering technologies/dissocubes.html [Last accessed 9 March 2009]
73. Baxter International Microprecipitation method for preparing submicron suspensions. US6607784; 2003
74. Asahi T, Masuhara H, Sugiyama T, et al. Process for producing fullerene dispersion liquid, and fullerene dispersion liquid. EP1939140A1; 2008
75. Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci 2007;30:367-374
76. Nanomorph-: Introduction. SOLIQS, Abbott Gmbh & Co., KG, Ludwigshafen, GermanyAvailable from: www.soliqs.com/ NanoMorph R.20.0.html [Last accessed 9 March 2009]
77. Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir 2007;23:9866-9874
78. ABRAXANE- (paclitaxel albumin-bound particles) for Injectable Suspension prescription information. Abraxis BioScience, LLC, Los Angeles, CA, 2008 Available from: www.abraxane.com [Last accessed 9 March 2009]
79. Desai NP, Soon-Shiong P, Magdassi S, Sahadevan DCNovel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof. WO9900113; 1999
80. 2. J Supercrit Fluids 2001;21(3):257-271
81. Shekunov BY, Chattopadhyay P, Seitzinger J, Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 2006;23:196-204
82. Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur J Pharm Sci 2006;27:299-310
83. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-186
84. Gassmann P, List M, Schweitzer A, Sucker H. Hydrosols: alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm 1994;40(22):64-72
85. Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci 2007;0(5):367-374
86. Peters K, Müller RH, Craig DQ. An investigation into the distribution of lecithins in nanosuspension systems using low frequency dielectric spectroscopy. Int J Pharm 1999;184:53-61
87. Ostwald W. Studies on the formation and inversion of solids. First paper: supersaturation and supercooling. Z Physik Chemie 1897;22:289-330
88. Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 2006;22:906-910
89. Lee J, Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release 2006;111:185-192
90. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Path 2008;36:43-48
91. Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339(1-2):251-260
92. Davis SS, Washington C, West P, et al. Lipid emulsions as drug delivery systems. Ann NY Acad Sci 1987;507:75-88
93. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996;4:129-140
94. ABELCET. Enzon Pharmaceuticals, Inc., Bridgewater, NJ, 2008. Available from: www.enzon.com/index.php?id=35 [Last accessed 9 March 2009]
95. Fahr A, Van HP, May S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251-265
96. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003;4:1277-1287
97. Visudyne. Novartis Pharmaceuticals Corp., East Hanover, N, 2008. Available from: www.visudyne.com/info/visudyne/ visudyne.jsp [Last accessed 9 March 2009]
98. Von Roenn JH, Lee S, Cianfrocca M, et al. Phase III study of paclitaxel (Pac) versus pegylated liposomal doxorubicin (PLD) for the treatment of advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS): an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):, 20503aa
99. Vincristine, DOXIL- (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. U.S. national Institutes of health, Bethesda, MD, 2009 Available from: clinicaltrials. gov/ct2/show/NCT00344422?intr=% 22Dexamethasone%22&rank=9 [Last accessed 9 March 2009]
100. Booser DJ, Esteva FJ, Rivera E, et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 2002;50(1):6-8
101. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 1975;394:483-491
102. Segarra I, Movshin Da L, Zarif L. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. J Pharm Sci 2002;91(8):1827-1837
103. FluidCrystal- NP Injection nanoparticles. CAMURUS AB, Lund, Sweden, 2009 Available from: camurus.verkstad.org/ index.asp?DocumentID=3& DocumentIDSub=8&Lang=&ShowSub= (2)&Show=(3) &main=Technologies [Last accessed 9 March 2009]
104. Johnsson M, Barauskas J, Norlin A, Tiberg F. Physicochemical and drug delivery aspects of lipid-based liquid crystalline nanoparticles: a case study of intravenously administered propofol. J Nanosci Nanotechnol 2006;6:3017-3024
105. Hemenway J, Stella VJ. Prodrugs and parenteral drug delivery (2.2.2). In: Stella, et al., editors, Prodrugs: challenges and rewards, Part I New York, NY: AAPS Press, Springer Science + Business Media, LLC; 2007. p. 218-81 . A key reference for prodrugs prepared for parenteral administration.
106. Johnsson M, Barauskas J, Tiberg F. Cubic phases and cubic phase dispersions in a phospholipid-based system. J Am Chem Soc 2005;127:1076-1077
107. Barauskas J, Johnsson M, Joabsson F, Tiberg F. Cubic phase nanoparticles (Cubosome): principles for controlling size, structure, and stability. Langmuir 2005;21:2569-2577
108. Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427-2437
109. Detoledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf 2000;22(6):459-466
110. Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42:33-58
111. Fechner J, Ihmsen H, Hatterscheid D, et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003;99:303-313 (Pubitemid 36909556)
112. Ueda Y, Matiskella JD, Golik J, et al. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. Bioorg Med Chem Lett 2003;13:3669-3672
113. Hanson BA. Evaluation of a phosphoryloxymethyl (POM) prodrug of camptothecin: Preformulation, formulation and pharmacokinetic studies. Ph.D. Dissertation, University of Kansas; 2002;181
114. Hanson BA, Schowen RL, Stella VJ. A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin. Pharm Res 2003;20:1031-1038
115. Liu X, Lynn BC, Zhang J, et al. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J Am Chem Soc 2002;124(26):7650-7651
116. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103-123
117. Takata J, Hidaka R, Yamasaki A, et al. Novel d-gamma-tocopherol derivative as a prodrug for d-gamma-tocopherol and a two-step prodrug for S-gamma-CEHC. J Lipid Res 2002;43:2196-2204
118. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
119. Vicent MJ. Polymer drug conjugates as modulators of cellular apoptosis. AAPS J 2007;9(2):E200-7
120. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetics study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents drug polymer conjugates. Clin Cancer Res 1999;5:83-94
121. Duncan R. N-(2-hydroxypropyl) methacrylamide copolymer conjugates. In: Kwon, editor, Polymeric drug delivery systems, New York, NY: Marcel Dekker; 2005. p. 1-92
122. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in caner therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006;5:1909-1917
123. Ducan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701 . A current review on the use of polymer prodrugs for cancer treatments.
124. Rowinsky EK, Rizzo J, Ocho L, et al. A phase I and pharmacokinetic study of camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003;21:148-157
125. Scott L, Evans T, Uao J, et al. Pegamotecan (EZ-246) a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a sing-agent phase-2 study. J Clin Oncol 2004;22(14S):4030
126. Bhatt R, De Vries P, Tulinsky J, et al. Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin. J Med Chem 2003;46:190-193
127. Singer JW, Bhatt R, Tulinsky J, et al. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74:243-247
128. Singer JW, De Vries P, Bhatt R, et al. Conjugation of camptothecin to poly-(L-glutamic acid). Ann NY Acad Sci 2000;922:136-150
129. Singer J, Baker B, De Vries P, et al. Poly-(L)-Glutamic acid-paclitaxel (CT-2103) [XYOTAX-], a biodegradable polymeric drug conjugate. Characterization, preclinical pharmacology, and preliminary clinical data. In: Maeda, et al. editors, Polymer drugs in the clinical stage advantages and prospects, New York NY: Kluwer Academic/Plenum Publishers; 2003. p. 81-99
130. Auzenne E, Donato NJ, Li C, et al. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian caricinoma. Clin Cancer Res 2002;8:573-581
131. Skwarczynski M, Kiso Y. Application of the O-N intramolecular acyl migration reaction in medicinal chemistry. Curr Med Chem 2007;14:2813-2823
132. Hayashi Y, Skwarczynski M, Hamada Y, et al. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. J Med Chem 2003;46:3782-3784
133. Agalloco JP. Thinking inside the box: the application of isolation technology for aseptic processing. Pharm Technol 2006;30:8-11
134. Yang G, Jain N, Yalkowsky SH. Combined effect of SLS and (SBE) (7M)-beta-CD on the solubilization of NSC-639829. Int J Pharm 2004;269:141-148
135. Tommasini S, Calabro ML, Raneri D, et al. Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin. J Pharm Biomed Anal 2004;36:327-333
136. Gladys G, Claudia G, Marcela L. The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta-cyclodextrin. Eur J Pharm Sci 2003;20:285-293
137. Basavaraj S, Sihorkar V, Shantha Kumar TR, et al. Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxypropyl-beta-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component. Pharm Dev Technol 2006;11:443-451
138. Valero M, Perez-Revuelta BI, Rodriguez LJ. Effect of PVP K-25 on the formation of the naproxen: beta-ciclodextrin complex. Int J Pharm 2003;253:97-110
139. Cirri M, Maestrelli F, Corti G, et al. Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization. J Pharm Biomed Anal 2006;42:126-131
140. Granero G, De Bertorello MM, Longhi M. Solubilization of a naphthoquinone derivative by hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and polyvinylpyrrolidone (PVP-K30). The influence of PVP-K30 and pH on solubilizing effect of HP-beta-CD. Boll Chim Farm 2002;141:63-66
141. Ribeiro L, Carvalho RA, Ferreira DC, Veiga FJ. Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies. Eur J Pharm Sci 2005;24:1-13
142. AI 850- Our reformulation of paclitaxel and potential bioequivalent of Abraxane-. Acusphere, Inc., Watertown, MA, 2008 Available from: www.acusphere.com/ product/prod-ai850.html [Last accessed 9 March 2009]
143. Straub JA, Chickering DE, Lovely JC, et al. Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res 2005;22:347-355
144. Straub JA, Chickering DE, Lovely JC, et al. Technology: the process particle formation and nanoparticles. CritiTech, Inc., Lawrence KS, 2007. Available from: www.crititech.com/technology.html [Last accessed 9 March 2009]
145. Straub JA, Chickering DE, Lovely JC, et al. Improving the clinical performance of drugs. Thar Pharmaceuticals, Inc., Pittsburgh, PA, 2008. Available from: www.tharpharma.com/index.htm [Last accessed 9 March 2009]
146. Telesso Technologies Limited, North Ryde NSW, Australia, 2008Available from: http://telesso.com/ [Last accessed 9 March 2009]
147. Bioral Technology. BioDelivery Sciences International, Raleigh, NC, 2009. Available from: www.biodeliverysciences. com/Bioral.php [Last accessed 9 March 2009]